MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

SpringWorks Therapeutics Inc

Затворен

СекторЗдравеопазване

46.51 11.53

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

41.08

Максимум

46.89

Ключови измерители

By Trading Economics

Приходи

-24M

-77M

Продажби

12M

62M

EPS

-1.04

Марж на печалбата

-125.586

Служители

368

EBITDA

-23M

-80M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+71.23% upside

Дивиденти

By Dow Jones

Следващи печалби

1.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-839M

3.3B

Предишно отваряне

34.98

Предишно затваряне

46.51

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

SpringWorks Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.02.2025 г., 07:03 ч. UTC

Придобивния, сливания и поглъщания

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10.02.2025 г., 16:38 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

11.02.2025 г., 10:54 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11.02.2025 г., 10:52 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

SpringWorks Therapeutics Inc Прогноза

Ценова цел

By TipRanks

71.23% нагоре

12-месечна прогноза

Среден 71.71 USD  71.23%

Висок 87 USD

Нисък 63 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за SpringWorks Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

7

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

44.13 / 47.505Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.